Compare Ginkgo Bioworks Holdings Inc (DNA) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.

While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.

HPE trades at $71.75, near its all-time high, with strong momentum driven by AI infrastructure demand. The stock has gained over 160% year-over-year and recently received a bullish upgrade from Daiwa. Recent earnings beats and a $1.2 billion AI server order from Vultr highlight operational strength. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026.

Outlook remains positive with AI-driven growth catalysts, though valuation multiples appear elevated. Key risks include execution on Juniper integration and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting limited near-term upside from current levels despite strong business momentum.